2. Signaling Pathways
  3. Cytoskeleton
  4. Collagen
  5. Collagen I Isoform
  6. Collagen I Inhibitor

Collagen I Inhibitor

Collagen I Inhibitors (8):

Cat. No. Product Name Effect Purity
  • HY-P990294
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7)
    		Inhibitor
    Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is an anti-mouse CD106/VCAM-1 IgG1 monoclonal antibody. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) reduces inflammatory response and oxidative stress by lowering p-STAT3 and reactive oxygen species (ROS) levels. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can alleviate cardiac inflammation and fibrosis by reducing the expression of collagen I and collagen III. Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) can be used for research on cardiovascular conditions such as hypertensive heart condition and subretinal fibrosis.
  • HY-N17650
    Salviamarinic acid A
    		Inhibitor
    Salviamarinic acid A is a water-soluble phenolic acid that can be extracted from Salvia miltiorrhiza with potent anti-pulmonary fibrosis activity. Salviamarinic acid A significantly increases cell viability, cell index, cell motility and E-cadherin expression, and reduces TGF-β1, α-SMA and Collagen I levels. Salviamarinic acid A can be used for pulmonary fibrosis research.
  • HY-P11826
    T2 peptide-1
    		Inhibitor
    T2 peptide-1 is a linear peptide derived from Lumican degradation. T2 peptide-1 exhibits activity against endometrial adhesion progression and ability to inhibit the Lumican−Collagen I interaction. T2 peptide-1 can be used for the research of liver fibrosis.
  • HY-182904
    GV-001
    		Inhibitor
    GV-001 is a selective and orally active HDAC6 inhibitor with an IC50 of 1.18 nM against HDAC6. GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD).
  • HY-123958
    SB772077B
    		Inhibitor
    SB772077B is a ROCK inhibitor. SB772077B has an anti-inflammatory activity and enhances aqueous outflow facility (OF) by inactivating RhoA/ROCK signal pathway. SB772077B significantly reduces the mRNA level of β-catenin and protein level of fibrotic markers, such as vinculin, fibronectin, collagen 1 A and vimentin. SB772077B also has vasodialatory activity and decreases pulmonary and systemic blood pressure. SB772077B can be used for glaucoma research and pulmonary hypertensive disorder research.
  • HY-180336
    LM9
    		Inhibitor
    LM9 is a potent, orally active MyD88 inhibitor. LM9 blocks TLR4/MyD88 binding, MyD88 homodimer formation, and TLR4/MyD88/NF-κB signaling pathway activation. LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. LM9 efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. LM9 can be used for fibrosis and atherosclerosis research.
  • HY-N11736
    12-O-Tiglyl-phorbol 13-dodecanoate
    		Inhibitor
    12-O-Tiglyl-phorbol 13-dodecanoate (TD13) is a potential inhibitor with anti-hepatic fibrosis activity, and it belongs to a series of derivatives of oral APOL2 inhibitors and anti-hepatic fibrosis agents. It shows no obvious toxicity in preclinical models. Compounds of the 12-O-Tiglyl-phorbol 13-dodecanoate series inhibit the expression of fibronectin, type I collagen and α-smooth muscle actin in hepatic stellate cells. 12-O-Tiglyl-phorbol 13-dodecanoate can be isolated from the Euphorbiaceae plant Euphorbia fischeriana, and it is applicable to the research of hepatic fibrosis.
  • HY-167201
    2ccPA
    		Inhibitor
    2ccPA is a Cyclic phosphatidic acid derivative. 2ccPA decreases ECM expression, increases the intracellular cAMP levels. 2ccPA decreases the protein expression levels of type I collagen, CCN2 and αSMA. 2ccPA has inhibitory effects on the progression of skin fibrosis by abrogating ECM production from activated skin fibroblasts.